SWOG S1416

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic



Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer


S1416 has an accrual goal of 235 in the main cohort and 98 in the brain metastases cohort for a total of 333 patients. The main cohort was reactivated on July 18, 2018. The brain metastases cohort will remain open. The overall accrual target for S1416 has not changed.